The Role of Social Deprivation and Cannabis Use in Explaining Variation in the Incidence of Psychotic Disorders: Findings From the EU-GEI Study.

epidemiology etiology social determinants of health social inequality substance use

Journal

Schizophrenia bulletin
ISSN: 1745-1701
Titre abrégé: Schizophr Bull
Pays: United States
ID NLM: 0236760

Informations de publication

Date de publication:
24 May 2024
Historique:
medline: 24 5 2024
pubmed: 24 5 2024
entrez: 24 5 2024
Statut: aheadofprint

Résumé

Recent findings suggest the incidence of first-episode psychotic disorders (FEP) varies according to setting-level deprivation and cannabis use, but these factors have not been investigated together. We hypothesized deprivation would be more strongly associated with variation in FEP incidence than the prevalence of daily or high-potency cannabis use between settings. We used incidence data in people aged 18-64 years from 14 settings of the EU-GEI study. We estimated the prevalence of daily and high-potency cannabis use in controls as a proxy for usage in the population at-risk; multiple imputations by chained equations and poststratification weighting handled missing data and control representativeness, respectively. We modeled FEP incidence in random intercepts negative binomial regression models to investigate associations with the prevalence of cannabis use in controls, unemployment, and owner-occupancy in each setting, controlling for population density, age, sex, and migrant/ethnic group. Lower owner-occupancy was independently associated with increased FEP (adjusted incidence rate ratio [aIRR]: 0.76, 95% CI: 0.61-0.95) and non-affective psychosis incidence (aIRR: 0.68, 95% CI: 0.55-0.83), after multivariable adjustment. Prevalence of daily cannabis use in controls was associated with the incidence of affective psychoses (aIRR: 1.53, 95% CI: 1.02-2.31). We found no association between FEP incidence and unemployment or high-potency cannabis use prevalence. Sensitivity analyses supported these findings. Lower setting-level owner-occupancy and increased prevalence of daily cannabis use in controls independently contributed to setting-level variance in the incidence of different psychotic disorders. Public health interventions that reduce exposure to these harmful environmental factors could lower the population-level burden of psychotic disorders.

Sections du résumé

BACKGROUND AND HYPOTHESIS OBJECTIVE
Recent findings suggest the incidence of first-episode psychotic disorders (FEP) varies according to setting-level deprivation and cannabis use, but these factors have not been investigated together. We hypothesized deprivation would be more strongly associated with variation in FEP incidence than the prevalence of daily or high-potency cannabis use between settings.
STUDY DESIGN METHODS
We used incidence data in people aged 18-64 years from 14 settings of the EU-GEI study. We estimated the prevalence of daily and high-potency cannabis use in controls as a proxy for usage in the population at-risk; multiple imputations by chained equations and poststratification weighting handled missing data and control representativeness, respectively. We modeled FEP incidence in random intercepts negative binomial regression models to investigate associations with the prevalence of cannabis use in controls, unemployment, and owner-occupancy in each setting, controlling for population density, age, sex, and migrant/ethnic group.
STUDY RESULTS RESULTS
Lower owner-occupancy was independently associated with increased FEP (adjusted incidence rate ratio [aIRR]: 0.76, 95% CI: 0.61-0.95) and non-affective psychosis incidence (aIRR: 0.68, 95% CI: 0.55-0.83), after multivariable adjustment. Prevalence of daily cannabis use in controls was associated with the incidence of affective psychoses (aIRR: 1.53, 95% CI: 1.02-2.31). We found no association between FEP incidence and unemployment or high-potency cannabis use prevalence. Sensitivity analyses supported these findings.
CONCLUSIONS CONCLUSIONS
Lower setting-level owner-occupancy and increased prevalence of daily cannabis use in controls independently contributed to setting-level variance in the incidence of different psychotic disorders. Public health interventions that reduce exposure to these harmful environmental factors could lower the population-level burden of psychotic disorders.

Identifiants

pubmed: 38788048
pii: 7681791
doi: 10.1093/schbul/sbae072
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : European Community's Seventh Framework Program
ID : HEALTH-F2-2010-241909
Organisme : São Paulo Research Foundation
ID : 2012/0417-0
Organisme : University Medical Centre Groningen
ID : 18-41
Organisme : NIHR UCLH BRC
Organisme : Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III
Organisme : European Union
Organisme : European Commission
Organisme : European Union-NextGenerationEU
ID : PMP21/00051
Organisme : CIBERSAM
Organisme : Madrid Regional Government (B2017/BMD-3740 AGES-CM-2)
Organisme : European Union Structural Funds
Organisme : European Union Seventh Framework Program
Organisme : European Union H2020 Program
Organisme : Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2
ID : 101034377
Organisme : Project AIMS-2-TRIALS
ID : 777394
Organisme : Horizon Europe
Organisme : National Institute of Mental Health of the National Institutes of Health
ID : 1U01MH124639-01
Organisme : Fundación Familia Alonso
Organisme : Fundación Alicia Koplowitz

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.

Auteurs

Vera Brink (V)

Department of Psychosis, University Center Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
PsyLife Group, Division of Psychiatry, University College London, London, UK.

Humma Andleeb (H)

PsyLife Group, Division of Psychiatry, University College London, London, UK.

Charlotte Gayer-Anderson (C)

ESRC Centre for Society and Mental Health, King's College London, London, UK.
Department of Health Service and Population Research, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Celso Arango (C)

Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, CIBERSAM, Madrid, Spain.

Manuel Arrojo (M)

Department of Mental Health and Drug-Addiction Assistance, Health Service of Galicia, Psychiatric Genetic Group IDIS, Hospital Clínico Universitario de Santiago de Compostela, affiliated center to Centro de Investigación Biomédica en Red de Salud Mental, Servicio Gallego de Salud, Santiago de Compostela, Spain.

Domenico Berardi (D)

Alma Mater Studiorium Università di Bologna, Bologna, Italy.

Miquel Bernardo (M)

Barcelona Clinic Schizophrenia Unit, Hospital Clinic de Barcelona, Barcelona, Spain.
Departament de Medicina, Institut de Neurociències (UBNeuro), Universitat de Barcelona (UB), Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.
CIBERSAM, ISCIII, Barcelona, Spain.

Julio Bobes (J)

Department of Medicine, Psychiatry Area, School of Medicine, Universidad de Oviedo, Centro de Investigación Biomédica en Red de Salud Mental, Oviedo, Spain.

Cristina Marta Del-Ben (CM)

Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.

Laura Ferraro (L)

Department of Biomedicine, Neuroscience, and Advanced Diagnostics, Section of Psychiatry, University of Palermo, Palermo, Italy.

Lieuwe de Haan (L)

Department of Psychiatry, Early Psychosis Section, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.

Daniele La Barbera (D)

Department of Biomedicine, Neuroscience, and Advanced Diagnostics, Section of Psychiatry, University of Palermo, Palermo, Italy.

Caterina La Cascia (C)

Department of Biomedicine, Neuroscience, and Advanced Diagnostics, Section of Psychiatry, University of Palermo, Palermo, Italy.

Antonio Lasalvia (A)

Department of Neuroscience, Biomedicine and Movement, Section of Psychiatry, University of Verona, Verona, Italy.

Pierre-Michel Llorca (PM)

Fondation FondaMental, Créteil, France.
CMP B CHU, Clermont-Ferrand, France.
Université Clermont Auvergne, Clermont-Ferrand, France.

Paolo Rossi Menezes (PR)

Department of Preventive Medicine, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Núcleo de Pesquina em Saúde Mental Populacional, Universidade de São Paulo, São Paulo, Brazil.

Baptiste Pignon (B)

Fondation FondaMental, Créteil, France.
Université Paris-Est-Créteil (UPEC) and AP-HP, Hôpitaux Universitaires « H. Mondor », DMU IMPACT, Psychiatry department and INSERM, IMRB, Translational Neuropsychiatry, Créteil, France.

Julio Sanjuán (J)

Department of Psychiatry, School of Medicine, Universidad de Valencia, Centro de Investigación Biomédica en Red de Salud Mental, Valencia, Spain.

José Luis Santos (JL)

Department of Psychiatry, Servicio de Psiquiatría Hospital "Virgen de la Luz", Cuenca, Spain.

Jean-Paul Selten (JP)

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.

Ilaria Tarricone (I)

Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorium Università di Bologna, Bologna, Italy.

Andrea Tortelli (A)

Institut National de la Santé et de la Recherche Médicale, U955, Créteil, France.
Pôle Psychiatrie Précarité, Groupe Hospitalier Paris Psychiatrie Neurosciences, Paris, France.

Giada Tripoli (G)

Department of Biomedicine, Neuroscience, and Advanced Diagnostics, Section of Psychiatry, University of Palermo, Palermo, Italy.
Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Eva Velthorst (E)

Department of Research, Mental Health Organization "GGZ Noord-Holland-Noord", Heerhugowaard, The Netherlands.

Bart P F Rutten (BPF)

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.

Jim van Os (J)

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.
Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.

Diego Quattrone (D)

Department of Biomedicine, Neuroscience, and Advanced Diagnostics, Section of Psychiatry, University of Palermo, Palermo, Italy.
National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK.
Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Robin M Murray (RM)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK.

Peter B Jones (PB)

Department of Psychiatry, University of Cambridge, Herchel Smith Building for Brain & Mind Sciences, Cambridge, UK.
CAMEO Early Intervention Service, Cambridgeshire and Peterborough National Health Service Foundation Trust, Chesterton Medical Centre, Cambridge, UK.

Craig Morgan (C)

ESRC Centre for Society and Mental Health, King's College London, London, UK.
Department of Health Service and Population Research, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Marta Di Forti (M)

National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK.
Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Hannah E Jongsma (HE)

Department of Psychosis, University Center Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Veldzicht Centre for Transcultural Psychiatry, Balkbrug, The Netherlands.

James B Kirkbride (JB)

PsyLife Group, Division of Psychiatry, University College London, London, UK.
Department of Psychiatry, University of Cambridge, Herchel Smith Building for Brain & Mind Sciences, Cambridge, UK.

Classifications MeSH